🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchMonthly semaglutide depot formulation — my results so far Page 3

Monthly semaglutide depot formulation — my results so far

tony_orlando Mon, Jul 22, 2024 at 3:23 PM 39 replies 2,686 viewsPage 3 of 8
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Jul 23, 2024 at 5:42 PM#11
roxy_nash said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

17 15lisa_labSD, adam_van, Dr.SurgeonPGH and 14 others
Reply Quote Save Share Report
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Jul 24, 2024 at 11:02 AM#12
SarahChen_PharmD said:
The mechanism that matters here is not stomach emptying, it is central.

This is exactly what I could not find anywhere else. Taking it to my next appointment.

18 16mike.trainer_LA, sarah_nash92, FitDadDave and 15 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Jul 25, 2024 at 4:21 AM#13
roxy_nash said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

19 17RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 16 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jul 25, 2024 at 9:40 PM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

20 18cory_ATX, lori_vegas, Dr.PulmRoch and 17 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jul 26, 2024 at 2:58 PM#15

Moderator note: a couple of off-topic posts removed.

21 19PurityPaulOR, MaxMetOK, MounjBrad and 18 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register